TBPH - Theravance Biopharma Inc
IEX Last Trade
8.25
0.040 0.485%
Share volume: 237,152
Last Updated: Fri 30 Aug 2024 09:59:54 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$8.21
0.04
0.49%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-09 | 2023-03-01 | 2023-05-10 | 2023-08-09 | 2023-11-09 | 2024-03-01 | 2024-05-15 | |
| Assets | |||||||||
| Total Assets | 360.761 M | 763.496 M | 607.400 M | 538.550 M | 446.630 M | 413.590 M | 381.999 M | 371.307 M | |
| Current Assets | 154.729 M | 511.718 M | 353.464 M | 261.338 M | 192.003 M | 161.690 M | 133.541 M | 124.294 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 9.391 M | 10.772 M | 9.195 M | 7.805 M | 8.756 M | 10.630 M | 13.641 M | 9.655 M | |
| Short Term Investments | 9.391 M | 10.772 M | 9.195 M | 7.805 M | 8.756 M | 10.630 M | 13.641 M | 9.655 M | |
| Total Receivables | 12.488 M | 14.114 M | 16.785 M | 12.270 M | 15.796 M | 17.057 M | 17.474 M | 14.664 M | |
| Current Cash | 132.850 M | 486.832 M | 327.484 M | 241.263 M | 167.451 M | 134.003 M | 102.426 M | 99.975 M | |
| Total Non-current Assets | 206.032 M | 251.778 M | 253.936 M | 277.212 M | 254.627 M | 251.900 M | 248.458 M | 247.013 M | |
| Property Plant Equipment | 12.531 M | 11.884 M | 11.875 M | 12.103 M | 9.553 M | 9.288 M | 9.068 M | 8.717 M | |
| Other Assets | 44.415 M | 239.058 M | 241.225 M | 245.497 M | 244.238 M | 241.776 M | 238.554 M | 237.460 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 360.761 M | 763.496 M | 607.400 M | 538.550 M | 446.630 M | 413.590 M | 381.999 M | 371.307 M | |
| Total liabilities | 710.570 M | 282.918 M | 165.600 M | 167.991 M | 166.469 M | 167.460 M | 169.004 M | 166.439 M | |
| Total current liabilities | 32.624 M | 142.132 M | 28.715 M | 26.184 M | 24.546 M | 25.368 M | 24.767 M | 21.662 M | |
| Accounts Payable | 3.074 M | 5.337 M | 1.554 M | 2.663 M | 1.569 M | 2.368 M | 1.524 M | 1.686 M | |
| Other liabilities | 2.608 M | 89.405 M | 91.478 M | 98.044 M | 99.402 M | 100.974 M | 99.001 M | 100.937 M | |
| Current long term debt | 2.624 M | 692.000 K | 6.753 M | 7.431 M | 9.160 M | 9.713 M | 3.923 M | 4.063 M | |
| Long term debt | 675.338 M | 51.381 M | 45.407 M | 43.763 M | 42.521 M | 41.118 M | 45.236 M | 43.840 M | |
| Other liabilities | 2.608 M | 89.405 M | 91.478 M | 98.044 M | 99.402 M | 100.974 M | 99.001 M | 100.937 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -349.809 M | 480.578 M | 441.800 M | 370.559 M | 280.161 M | 246.130 M | 212.995 M | 204.868 M | |
| Common stock | 76.270 M | 75.515 M | 67.332 M | 62.934 M | 56.682 M | 52.361 M | 49.235 M | 48.283 M | |
| Retained earnings | -1.760 B | -843.549 M | -853.911 M | -875.999 M | -891.644 M | -900.594 M | -909.104 M | -920.768 M |